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NEURON-MICROGLIA INTERACTIONS IN MOTOR NEURON 
DEGENERATION. THE INFLAMMATORY HYPOTHESIS IN AMYOTROPHIC 
LATERAL SCLEROSIS REVISITED 
 
ABSTRACT 
Research into the pathogenesis of amyotrophic lateral sclerosis (ALS) has obtained 
notable gene discoveries, although, to date, only progress with regard to treatment has 
been very modest. Currently ALS is considered a multifactorial disease that presents 
diverse clinical presentations, ranging from a monogenic inherited disease to an 
autoimmune pathology, and develops with misfolded protein aggregation and 
neuroinflammation. An important factor related to ALS pathogenesis is the microglial 
activation associated with degenerative motor neurons. This activation leads to changes 
in the expression of a wide range of genes related to phagocytosis and inflammation, 
and to profound modifications in the dynamic interactions between neurons and glial 
cells. Overactivation and deregulation of microglial activity causes deleterious effects 
and leads to neuronal death. However, the involvement of microglia in non-
inflammatory functions challenges our concept of neuroinflammation and opens up new 
possibilities for the study of the pathophysiological mechanisms of ALS. In this review 
we summarize the current knowledge on the adaptive interactions between neurons and 
microglia in ALS. We also discuss the hypothesis that controlling the extent of 
microglial activation and neuroinflammation may have clinical and therapeutic benefits 
for the condition. 
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Amyotrophic lateral sclerosis (ALS) is the most common adult motor neuron disease. 
Known in the US as Lou Gehrig’s disease, after the legendary American baseball first 
baseman (1903-1941). ALS progresses rapidly and is invariably fatal. ALS afflicts some 
350,000 people a year worldwide, with a prevalence of 2-4 per 100,000 individuals. 
Before the age of 65, slightly more men than women develop ALS, with the only 
striking female predominance appearing in bulbar-onset patients. This sex difference 
disappears after age 70 [1–3]. There is no curative treatment, and the drugs currently 
available have an imperceptible action on the clinical course [4].  
ALS was described for the first time 140 years ago [5]. Despite the identification of 
several single gene mutations with more than 10 loci, mostly in autosomal dominant 
familial cases (fALS), ALS is a multisystem neurodegenerative disease whose origin 
and progression are not clearly understood [6]. For the familial forms, fifteen years after 
the initial discovery of mutations in the enzyme Cu/Zn superoxide dismutase (SOD1), a 
diversity of new genetic mutations have been progressively identified, including TAR 
DNA binding protein-43 (gene TARDBP, protein TDP-43) and the C9orf72 gene, until 
now the most common mutation underlying fALS. Recent data from family histories 
suggest a continuum of heritability between fALS and sporadic ALS (sALS), with a 
progressive decrease in the frequency of mutations in ALS genes [7,8].  
Except for the rare juvenile form (especially the very aggressive fused in sarcoma 
(FUS) gene mutation form [9]) the age range for developing ALS is quite broad, 
between 45 and 60 years [10]. The progressive atrophy and loss of upper (corticospinal) 
and lower (spinal and bulbar) specialized neurons lead to muscle atrophy, weakness and 
spasticity, and rapidly to paralysis [11]. In a diversity of phenotypes, the 
extrapyramidal, cerebellar, sensory or autonomic systems are also affected [12]. (See 

































































the ALS Research Forum webpage [13] for detailed information). The approximately 20 
per cent of ALS patients who develop frontotemporal dementia (FTD), adds another 
dimension the disease’s genetic and phenotypic variability [14-17]. Together with its 
large clinical heterogeneity (Figure 1a) even within the familiar forms [18-20] the 
absence of specific biomarkers delays ALS diagnosis and strongly limits an early 
neuronal therapeutic approach.  
Until now, the higher ALS prevalence in specific groups of patients (football players 
[21-23], veterans of the Gulf War [24,25] or farmers with elevated pesticide and/or 
fertilizer exposure [26–29]) has not helped unravel the cascade of events or the driving 
force underlying the disease. Several pathological mechanisms such as genetic factors, 
environment, autoimmunity, oxidative stress, excitotoxicity, microglial activation, 
impairment in filament organization and neuronal transport, and misfolded proteins 
have been proposed as possible explanations of ALS heterogeneity [30,31]. Among 
them, misfolded protein aggregation and neuroinflammation are the only common 
mechanisms present in most ALS patients (Figure 1b). The recent implication of 
microglia in non-inflammatory functions challenges our concept of neuroinflammation 
and opens up new avenues in the study of ALS pathophysiology. In this review we 
discuss the current knowledge of these mechanisms, placing special emphasis on the 
non-inflammatory dynamic interactions between neurons and microglia in ALS.  
 
2. GENETICS OF ALS  
The hunting for genetic mutations causative for ALS has accumulated substantial body 
of research, with a wide range of results. According to the ALSoD database [32], 126 
genes had been associated with ALS by September 2015. Of these, defects in six genes 
have been found to be main causes of the disease [33], and a growing number of genes 

































































such as the fractalkine receptor (CX3CR1), UNC13A, KIFAP3, EPHA4 and SLC11A2 
have been associated with ALS susceptibility, progression or prevalence. [34–38] 
(Table 1) Multiple mutations of a sole gene also lead to graded phenotypic affectations. 
For example, the 166 widely dispersed exonic mutations of the Cu/Zn superoxide 
dismutase (SOD1) gene coding for a mitochondrial enzyme of only 153 amino acids 
that neutralize toxic superoxide radicals are associated with some 20% of fALS and 1-
3% of sALS, all characterized by a large heterogeneity in their presentation [39-43].  
However, toxicity of SOD1 exon mutations is related not to altered enzyme activity but 
to the formation of SOD1 misfolded protein aggregates [44-47]. Characterized in motor 
neurons and glial cells, wild-type and mutant SOD1 aggregates [39,48] correlate with a 
similar ALS phenotype [49,50] and also in mice with wild-type SOD1 causing ALS 
[51]. Inflammation and neuronal death represent a cascade events that are also present 
in other neurodegenerative diseases characterized by misfolded protein aggregates like 
the protease-resistant prion protein, Amyloid-β, Tau, or α-synuclein [52,53].  
This toxic formation of protein aggregates applies to many other native and mutated 
misfolded proteins characterized in ALS patients, like the vesicle associated membrane 
protein (VAMP)-associated protein (VAPB), TARDBP, FUS, and angiotensin (ANG) 
genes [33,54], and has been extended by the discovery of frequent combined C9orf72 
gene mutations that facilitate native protein aggregation (see below). The recently 
discovered TBK1 gene mutations modify two main pathways, inflammation and 
autophagy [55], and may alter microglial adaptation to neuronal damage, in particular 
the engulfment of dying spinal cord neurons [56].  
Different VAPB mutations combined with other ALS-relevant mutations, like those in 
C9orf72 [57,58], have been identified in fALS patients. The formation of mutant VAPB 
cytoplasmic aggregates triggers Ca
2+
 dependent aberrant functioning of the endoplasmic 

































































reticulum (ER) and Golgi apparatus. This also occurs in surrounding cells in which 
wild-type VAPB aggregation takes place, leading to motor neuron degeneration [59,60].  
The recent discovery in patients with and without fALS history that the C9orf72 gene 
defect can cause ALS [61,62] has added a new dimension to the disease’s complexity. It 
challemged the present fALS and sALS classification (Figure 1b), and offered a 
convergent explanation of ALS pathogenesis that includes RNA dys-metabolism and 
proteinopathy [63]. In fact, the common genetic variations found in both genetic and 
sporadic ALS patients by genome-wide association studies [64,65] include a diversity 
of factors that support ALS susceptibility and heterogeneity, and argue for subgroups of 
both fALS and sALS along an ALS continuum.  
 
3. ALS AS A MISFOLDED PROTEIN DISEASE  
The genetic data suggest that alterations in RNA processing (modified protein 
synthesis) and proteinopathy (modified protein degradation) are key to both fALS and 
sALS pathogenesis. For example, 97% of all sporadic cases present TDP-43 
proteinopathy, characterized by cytoplasmic TDP-43 ubiquitinated aggregates [66]. In 
45% of all sporadic FTD cases, and in numerous genetic mutations of fALS-FTD, TDP-
43 proteinopathy also occurs [16,67]. Multiple forms of ALS may then be viewed as 
different manifestations of a misfolded protein disease (MPD), in which a misfolded 
protein like SOD1, VAPB or TDP-43 develops insidiously and initiates an early 
neurodegenerative process that manifests clinically in middle or late life in both sALS 
and fALS. 
In all MPDs, the pathogenic mechanism represents the initial aggregation and CNS 
deposition of a misfolded protein in specific neurons and/or astroglia that grow 
following a crystallization-like process [68–70]. Many of these proteins are 

































































metalloproteins in which the ionized metal participates directly in the protein 
conformation and function. Besides the mutation hotspots of the coding genes identified 
in fALS and sALS and associated with a proteinopathy, the age-related metal 
dyshomeostasis allows variations of metalloprotein conformation and activity that may 
also result in intracellular aggregates. For example, the variety of binding affinities and 
binding sites reported for copper to SOD1 indicate that, through these numerous 
possible interactions, the copper level may directly drive the diversity of the states and 
functions of these proteins, in particular in an insoluble state [71]. This possibility may 
pave the way for new therapeutic strategies able to control the misfolded protein metal 
dyshomeostasis (see below). 
Elaborate systems have evolved to protect cells from misfolded proteins. An example is 
the ubiquitin-proteasome system, which degrades the newly translated proteins that 
failed to fold correctly [72,73]. In PMD, misfolded proteins are not removed and they 
aggregate within the cell. As seen in the frontal cortex and spinal cord from sALS 
patients and in the SOD1
G93A
 spinal cord in mice, these aberrant intracellular 
accumulations result in ER stress, proteasomal impairment and increased energy 
demand, progressive Golgi damage, and mitochondrial dysfunction with massive 
oxidative stress [53,74–76]. In addition, these aggregates from dying neurons/astrocytes 
or mediated by exosomes activate a microglial phagocyte phenotype to remove 
aggregates and cellular debris [77,78] (figure 2) and extends the damage to the 
surrounding cells mostly via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptor-mediated excitotoxicity in spinal motor neurons [79]. Similar results 
are observed with the Guam population diet which is rich in β-methyl-amino-L-alanine 
(BMAA). It chronically activates AMPA receptors, and in combination with other 
insults or with genetic predisposition, leads to ALS [80,81]. 

































































Glia participation in the neurodegenerative process depends on increased energy 
consumption [82,83]. Increased energy consumption is also required for neurons to 
engulf aggregates, repair damage or enter in apoptosis [84–86]. In these conditions, 
glucose transport to CNS is not sufficient to cover demand, and lactate is formed within 
astrocytes and sent to neurons for its complete oxidation [87,88]. As a result, the tissue 
pH decreases, which alters protein folding and induces aggregate formation, as observed 
with Amyloid-β [89]. In ALS, this dynamic adaptation of the glial phenotype to the 
graded metabolic and structural modifications results in an overproduction of 
neurotoxic molecules and chronic neuroinflammation (Figure 2) which drives, at least 
in part, the disease progression [77,90-92] . 
The pleiotropy of the ALS genes coding for proteins involved in this pathogenic process 
represents, in fact, a convergent mechanism that helps explain the broad spectrum and 
peculiar complexity of ALS clinical manifestations [93]. The presence of alterations in 
interrelated metabolic pathways has also been confirmed by blood analysis of ALS 
patients [94]. Currently, there is a growing consensus among clinicians and researchers 
that the degeneration and death of upper and lower motor neurons relies on the 
convergence of various altered metabolic processes in which neuroinflammation is 
always present and related with high energy consumption and misfolded protein 
formation (Figure 1b). For these reasons, energy metabolism and nutritional status are 
factors that help to explain the penetrance variability of ALS genes [95,96]  
 
4. ENERGY METABOLISM AND NUTRITION IN ALS 
Whole body energy metabolism is impaired in ALS, and body mass index and overall 
nutritional status at disease onset are independent predictors of survival in ALS [94]. A 
recent metabolomics study identified alterations characteristic of an increased glycolysis 

































































and lipolysis in order to produce more adenosine triphosphate (ATP) and thus to 
facilitate energy consuming processes [97]. This overall increase in energy demand 
reflects major cellular activity in an atempt to control the ALS neurodegenerative 
process taking place and to activate CNS and muscle repair. To ensure very high levels 
of ATP production from carbohydrate and lipid oxidation, mitochondria increase their 
activity and number, resulting in enhanced release of reactive oxygen species (ROS) 
[98]. In close contact with the nucleus, which also produces ATP from the ADP-ribosyl 
residues after sudden extensive changes in chromatin [99] (perhaps the ones caused by 
the heterogeneous ribonucleoproteins (hnRNPs) identified in ALS) proteasome 
becomes especially important for maintaining cellular homeostasis through degradation 
of ubiquitinated factors like Drp1, which control mitochondria fusion and fission and 
the ubiquitinated misfolded ALS proteins [100]. In addition, reduced glucose uptake 
and metabolism consequent to increased glucocorticoid signaling pathways cannot be 
discarded [101–103]. 
In fact, the on-going ALS neurodegenerative process is the result of two dynamic tissue 
mechanisms, one neurotoxic and an adaptive neuroprotective. The high-energy demand 
present in ALS must be part of this second mechanism, which remains efficient despite 
its elevated ROS production and progressive mitochondria and proteasome damage, and 
the altered ER-mitochondria interactions. In any case, the importance of rich-energy 
nutrition must be considered a key aspect of the patient care. In this framework, the 
Guam population, whose etiology of ALS correlates significantly with picking, 
processing, and eating cycad seed flour rich in neurotoxins such as BMAA, a potent 
glutamate agonist at both AMPA and kainate receptors [104] exemplifies the relevance 
of nutritional factors [105,106]. As such recent clinical trials have highlighted the 
importance of controlling ALS patient nutrition, with interventions from 

































































complementary approaches (ClinicalTrials.gov identifier: NCT00983983) or with 
administration of olanzapine, a weight gain drug (ClinicalTrials.gov identifier: 
NCT00876772). 
 
5. REFINING CONTROL OF NEUROINFLAMMATION IN ALS 
Until a few years ago, little was known about microglia adaptation and participation in 
ALS, and the microglia’s direct and permanent involvement in the disease is a recent 
discovery. ALS pathophysiology includes a chronic microglial reaction in the 
surroundings of degenerative motor neurons [107]. In patients with ALS, microgliosis 
appears specifically in the motor cortex, along the corticospinal tract, and in the ventral 
horn of the spinal cord [108–110]. Although the molecular mechanisms of this 
neuroinflammation have not been clarified, it has been demonstrated that activation of 
microglia in the ALS-injured CNS leads to release of cytokines, chemokines, and 
neurotrophic or neurotoxic factors that stimulate astrocytes and mobilize cells from the 
peripheral immune system [111–113]. These cells in turn produce new cytokines 
creating a chronic inflammatory response [111,112].  
In the healthy CNS, microglia present a highly ramified morphology, express receptors 
for neurotransmitters and neuromodulators [116–118], dynamically monitor the 
neuronal microenvironment and actively respond to neuronal activity as an integrated 
part of the "quad-partite" synapse [119–121]. This non-inflammatory microglial activity 
has important roles in CNS development eliminating the excess of neurons and 
controlling synaptic pruning and maturation of excitatory synapses (see [122] for a 
review). In the adult brain, the microglia is an important player in the regulation of 
synaptic plasticity [121,123,124] and in clearing newborn adult hippocampal 
progenitors [125]. Thus, there is evidence of the involvement of microglia in the control 

































































of long-term potentiation [126–128] long-term depression [129], synaptogenesis 
[130,131], and in sensing and eliminating defunct synapses [119].  
These non-inflammatory roles of microglia involve dynamic interactions with neurons. 
Microglia are maintained in surveillance via signaling between fractalkine (CX3CL1) 
and its G-coupled protein receptor, CX3CR1. In the CNS, fractalkine is expressed by 
neurons as a membrane-bound glycoprotein, from which a soluble chemokine can be 
proteolytically released [132,133]. Fractalkine modulates migration, motility, and 
activation of microglia by interaction with the CX3CR1, which is specifically expressed 
in microglia [112]. In turn, the interaction fractalkine-CX3CR1 is required for proper 
maturation of excitatory synaptic transmission [134]; mice lacking CX3CR1 show 
persistent alterations in hippocampal glutamatergic transmission [135]. 
When microglia become reactive, their morphology changes, ranging from enlargement 
of processes and hypertrophy of the cell body to acquisition of an amoeboid shape. 
Besides these morphological alterations, reactive microglia also release cytokines and 
upregulate a variety of surface molecules[113,136–138]. Classically, microglia have 
been considered as resident macrophages of the CNS and the concept of macrophage 
polarization has been extrapolated to explain reactive microglia activity [139]. 
According to this paradigm, M1 (or classically activated) microglia present 
inflammatory activity, whereas M2 (or alternatively activated) microglia have tissue 
repair functions [107]. Initially a pro-inflammatory M1 phenotype aims to protect and 
repair damaged tissue but prolonged and excessive inflammation is cytotoxic and 
induces neuronal death [136–138]. Pro-inflammatory microglia promote a neurotoxic T-
cell response and are cytotoxic owing to the secretion of nitric oxide (NO) and classical 
pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor 
(TNF)-α, ROS production and the reduction of protective trophic factor expression 

































































[142]. In addition, chronically activated microglia may become increasingly 
dysfunctional and may directly participate in the development of secondary tissue injury 
[143]. In contrast, M2 neurorestorative microglia activity includes the production of 
high levels of anti-inflammatory cytokines like IL-4, IL-10, neurotrophic factors, and 
proteins such as insulin-like growth factor (IGF)-1, arginase-1 and Ym-1 [144–146]. 
However, the M1 vs. M2 paradigm of macrophage activity has recently been 
reappraised since it appears to be at odds with the recent data emerging from 
epigenetics and genome-wide transcriptional studies [112,147]. New findings have also 
established that microglia are a unique cell population, distinct from macrophages 
[112,148]. Analysis of acutely isolated microglia from SOD1
G93A
 tg mice revealed 
upregulation of both neuroprotective and toxic factors related with ALS [112]. 
SOD1
G93A
 microglia upregulated the expression of IGF-1 and progranulin, two 
microglial factors known to confer neuroprotection and increase survival in ALS 
models [149,150], and progranulin mutations are major known genetic causes of ALS-
FTD [151]. With respect to the neurotoxic factors, metalloproteinase 12 and optineurin 
are upregulated in SOD1
G93A
 microglia [112]. Mutations in optineurin cause fALS 
[152,153] and deregulate interferon signaling [154], while metalloproteinase inhibition 
increases survival in ALS mice [155]. More interestingly, in the same study SOD1
G93A
 
microglia also increased the expression of genes related with Alzheimer’s, Huntington 
and Parkinson’s diseases but not of genes related with lipopolysaccharide-induced 
microglial activation [112].  
Thus, the M1-M2 dichotomy does not seem the best-suited concept for explaining the 
microglial response to motor neuron injury. Rather, microglia become reactive through 
expression changes in a wide range of genes that mediate the acquisition of new cell 
functions. This means that, at each moment, the balance of secreted molecules from the 

































































microenvironment determines a spectrum of microglial phenotypes that also vary with 
the time and intensity of neuron damage [112,145]. However these phenotypes are 
classified, microglia respond with a large diversity of signals, some of them detrimental 
and others restorative, which modulate neuroinflammation and thus interfere with ALS 
progression (Figure 3). 
Astrocytes also participate in the inflammatory mechanisms associated with motor 
neuron degeneration [156–158] and may play a dual role. Like microglia, astrocytes 
exert both toxic and protective effects on neurons in a context-dependent manner 
(Figure 3). In fact, they may represent a diverse population of genetically tractable cells 
that mediate neural circuit–specific roles in health and disease (see [159] for a review). 
Astrocyte activation has been described in the spinal cord, motor cortex and subcortical 
white matter [160,161] of ALS patients. In the SOD1
G93A
 tg mouse, astrogliosis is 
concomitant with motor neuron loss [161,162]. 
Astrocytes express MHC molecules and can present antigens to primed memory T cells 
[163]. They respond to neuronal injury by releasing acute-phase proteins such as α1-
antichymotrypsin and α2-macroglobulin, complement proteins, and neuronal growth 
factors and cytokines [116]. In general, their neurotoxic activity is mediated via 
activation of pattern recognition receptors such as Toll-like receptors. After receptor 
activation, astrocytes secrete cytokines like CCL2, IL-6 and other neurotoxic factors 
that enhance the inflammatory response [108,164,165]. Their neuroprotective effects 
are mediated by an homeostatic control of neuronal activity [159,166] and the release of 
neurotrophic factors such as nerve growth factor and IGF-1 [165].  
Astroglia also contribute to motor neuron degeneration through non-immune 
mechanisms that may be associated with abnormal astrocyte activity rather than with 
astrogliosis. For example, in ALS patients and in ALS animal models, astroglia lead to 

































































glutamate excitotoxicity due to a decreased expression of glutamate transporter-1 
[167,168]. A recent study has related the increased expression of connexin 43 in the 
motor cortex and spinal cord of ALS patients, and enhanced gap junction coupling in 
SOD1
G93A
 mice, with the course of the disease [169]. The subsequent increased hemi 
channel-mediated activity and elevated intracellular calcium levels suggest excessive 
astrocyte exchange of metabolites, ions and second messengers, which results in an 
astrocyte-mediated toxic effect on motor neurons.  
 
6. IS ALS A NEUROINFLAMMATORY DISEASE? 
Research into the pathogenesis of ALS had conventionally assumed that 
neuroinflammation was a response to motor neuron injury and extracellular protein 
deposition. However, studies in SOD1 tg mice evidenced microglial activation even 
before motor neuron cell death [170,171], which suggested the hypothesis that 
neuroinflammation might contribute to ALS pathogenesis [107]. Currently, there is 
increasing evidence linking ALS molecular hallmarks with modifications in microglial 
activity or the immune system response. For example, TDP-43 and the p65 subunit of 
the nuclear factor-κB (NF-κB) are increased in the spinal cord of sALS patients when 
compared with healthy individuals [172]. TDP-43 interacts and co-localizes with p65 in 
microglia and neurons from ALS patients and mice expressing wild-type and mutant 
TDP-43 transgenes, but not in cells from healthy individuals or non-transgenic mice 
[172,173]. Thus, TDP-43 acts as a co-activator of p65, and microglia expressing larger 
amounts of TDP-43 produced more pro-inflammatory cytokines and neurotoxic 
mediators after activation [173]. At the functional level, inhibition of NF-κB activity in 
TDP-43 mice reduces denervation in the neuromuscular junction and ALS disease 

































































symptoms [174]. TDP-43 deregulation thus contributes to ALS pathogenesis, in part by 
promoting the inflammatory activity of the microglia.  
Similarly, C9orf72 plays a key role in innate immune cell function. Mice lacking 
C9orf72 develop splenomegaly nad lymphadenopathy and accumulate swollen 
macrophage-like cells [175]. Loss of C9orf72 in mice also leads to macrophage and 
microglial dysfunction and age-related neuroinflammation similar to that described in 
C9orf72 fALS [175]. Again, these new findings raise the possibility of a dual 
pathogenic mechanism, in which the effects of microglial dysfunction from decreased 
C9orf72 expression combine with toxic by-products in neurons to promote 
neurodegeneration (Figure 2).  
Immune actions may then precede ALS pathology and may be sufficient to cause it, 
suggesting that ALS is an autoimmune disease. A growing body of evidence supports 
this hypothesis. For example, circulating myeloid cells of ALS patients have a pro-
inflammatory phenotype [90,176], while regulatory T lymphocytes are decreased, 
enhancing neuroinflammation and disease progression [177]. Also, the up-regulation of 
inflammatory genes in arrays on samples from ALS patients suggests the involvement 
of immune actions in the ALS pathogenesis [178–180]. Some other studies have related 
motor neuron disease with autoimmune neuromuscular disorders. Around 30% of ALS 
patients present decrement on repetitive nerve stimulation [181], and the risk of ALS is 
increased in people with concomitant myasthenia gravis [182]. This combination of 
ALS and myasthenia gravis has been reported to occur non-stochastically [183] and, 
although the reasons for the coincidence are unknown, it may involve a link between the 
immune system and ALS [156]. Taken together these results suggest that immune 
processes may drive ALS pathology independently of neural processes, exacerbating 
motor neuron injury and feeding a cyclic process that sustains neurodegeneration.  

































































As in other aspects of the disease, the nature of neuroinflammation in ALS is 
heterogeneous. In many cases adaptive immune cells may drive the pathological 
process, a feature that defines ALS as a neuroinflammatory disease rather than a 
neurodegenerative disorder [139]. However, this concept is far from being consolidated: 
it remains unclear how and when the immune system impacts the course of ALS, and it 
stills needs to be clarified whether an immune mechanism is involved in all patients. 
 
7. MICROGLIA MAY DRIVE ALS PATHOPHYSIOLOGY 
A key aspect of CNS function is the dynamic interaction between neurons and 
microglia. Therefore dysfunction of microglial non-inflammatory activity may 
contribute to pathological processes [184,185]. For exemple, excessive activation of 
microglial CD33 was found to upregulate synapse removal in Alzheimer’s disease 
patiens and mouse models [186,187]. Also, altered microglial brain-derived 
neurotrophic factor signaling has been associated with neuropathic pain [123]. In this 
line, the axis fractalkine-CX3CR1 participates in the control of microglial dysfunction. 
Microglial CX3CR1, involved in neurotrophic fuctions, is upregulated in many 
pathological conditions [188]. The role of CX3CR1 in the control of neuroinflammation 
has been extensively studied in the CX3CR1-EGFP mouse line. Although the 
consequences of CX3CR1 deletion in microglia largely depend on the mouse model 
used, the overall idea is that a lack of CX3CR1 leads to a hyperactivity of microglia in 
the diseased brain, thereby unleashing potential neurotoxic properties [113,189,190]. 
However, other evidence suggests that fractalkine sustains neuroinflammation and 
contributes to neurotoxicity (see [191] for a review). In any case, CX3CR1 signaling 
impairment has a direct influence on neurodegenerative diseases associated with 
neuroinflammation, microglia and/or T-cell recruitment [192,193].  

































































In a cohort of Spanish sALS patients, a genetic association was described between the 
V249I and T280M variants in the human CX3CR1 gene and the progression rate and 
survival time [34]. This association has also been reported between these two CX3CR1 
gene variants and some other inflammatory diseases, including multiple sclerosis, age-
related macular degeneration, AIDS, and coronary disease [194]. V249I and T280M 
genetic variants affect the activity of the CX3CR1 protein by reducing its affinity to 
fractalkine [195]. In animal models, CX3CR1-/- knockout mice inbred with the 
SOD1
G93A
 tg ALS model present a worsened disease outcome, more extensive neuronal 
loss and increased microglial activation [196]. As CX3CR1 is involved in microglial 
neurotrophic function (Figure 3), its reduced activity may exacerbate the pro-
inflammatory activity of microglia.  
What still remains to be established is whether the fractalkine-CX3CR1 axis is affected 
in the diseased brain. There are few reports of fractalkine concentration in the brain and 
CX3CR1 expression in microglia during the course of disease. Cardona et al. [188] 
detected a rather high concentration of free fractalkine in the brain, which suggests a 
constitutive release under physiological conditions. In multiple sclerosis or epilepsy, the 
CNS levels of fractalkine and/or CX3CR1 were found either unchanged or increased 
[197,198], indicating that the inhibitory function of the fractalkine-CX3CR1 axis is not 
generally weakened under diseased conditions. 
Microvesicles (MVs) and exosomes are considered important players in the dynamic 
interactions between neurons and glia. In the CNS, neurons, microglia, astrocytes and 
oligodendrocytes release MVs and exosomes with different sizes and contents into the 
extracellular space. These particles can move freely through the extracellular medium 
and interact with different cell types by as yet undetermined mechanisms [199]. MVs 
carry and may shuttle specific proteins and noncoding nucleic acids such as microRNAs 

































































(miRNAs) [200]. In fact, some miRNA may be found in MVs at higher concentrations 
than in cells [201]. For these reasons, besides their potential as disease biomarkers 
[202], MVs and exosomes are considered to have a role in the pathogenesis and 
dissemination of inflammatory diseases.  
The cell-to-cell transmission of TDP-43 and SOD1 misfolding, which is propagated by 
prionic mechanisms (see [52] for a review), now appears to be mediated by MVs 
trafficking. A recent study provides evidence for a primarily microvesicular intercellular 
spread of TDP-43 aggregates [203], and both neuronal and astroglial MVs have been 
implicated in the propagation of pathogenic misfolded SOD1. In vitro, motor neuron 
NSC-34 cells overexpressing wild type and mutant SOD1 secreted this protein via 
exosomes [204]. Astrocytes expressing mutant SOD1 release a high amount of 
exosomes carrying the protein and promote motor neuron death [205]. Interestingly, 
MVs from activated astroglia also transfer amino-acid transporter-1 [206], suggesting a 
possible role for them in the extracellular mechanism that curtails excitotoxicity. 
There is growing evidence of the involvement of miRNA deregulation in ALS 
pathogenesis [207–211]. Changes in miRNA expression have been found in patients 
and the SOD1
G93A
 mouse [176,212,213] reflecting a dysfunction of the expressed RNA 
binding proteins involved in ALS. miRNAs are stable in cerebrospinal fluid, serum and 
other body fluids as exosomal cargos [214] and their concentrations are also modified in 
ALS [215] suggesting that the dysfunction of RNA binding proteins in ALS is systemic. 
In serum of fALS patients, specific miRNAs non-related with the mutated gene are 
downregulated already in presymptomatic disease [216,217], whereas serum miRNA 
profiles are far more heterogeneous in sALS patients [218]. Other exosomal miRNAs 
are upregulated in ALS [219]. Some are components of the innate immune system and 

































































modify the pro-inflammatory NF-κB signaling pathway [220], indicating, again, a role 
for the immune system in ALS pathogenesis. 
Finally, reactive microglia release MVs and exosomes, which may have a dual role in 
motor neuron degeneration (Figure 3). On the one hand, MVs released by reactive 
microglia carry pro-inflammatory cytokines [221] and induce an inflammatory reaction 
in target cells [222]. Microglia-derived MVs also promote precipitation of misfolded 
proteins in Parkinson’s and Alzheimer’s disease models [223,224]. On the other hand, 
microglia stimulated with interferon-γ release exosomes that confer protection on 
surrounding cells [225]. Thus, different stimuli may trigger the microglial release of 
MVs with different composition and properties, as already described for macrophages 
and monocytes [226,227]. If true, microglial activation will lead to increased secretion 
of MVs, which differ in composition and are associated with ALS pathological 
processes with distinct roles. This possibility may open up new avenues in the 
development of treatments for ALS. Currently it is considered that, by engineering 
MVs, it will be possible to enhance the protective microglial phenotype in order to 
curtail neuroinflammation and promote tissue repair. 
 
8. NEUROINFLAMMATION AND ALS TREATMENTS  
The difficulty of developing effective treatments for ALS is explained, at least in part, 
by its heterogeneity and the presence of both functional and structural on-going cell 
damage. For years, the multiple ALS phenotypes and the identification of many 
mutations in the SOD1 gene that could not explain the disease were not little help in 
guiding pharmacological research; riluzole, introduced in 1995, is presently the sole 
authorized treatment, with limited efficacy and a high financial cost [228]. Since the 
1990s, clinical trials with many other drugs have mostly yielded negative results, and 

































































there is an urgent need to define new and effective therapeutic strategies and improve 
clinical trials [229–231]. 
Protein aggregation and neuroinflammation are common features of the chronic course 
of ALS. Therefore the molecular mechanisms underlying these factors are potentially 
amenable to therapy. In this line, the compound BIIB067, a drug designed to reduce the 
production of SOD1, is currently in a phase I clinical trial (ClinicalTrials.gov ID: 
NCT02623699) [231]. With respect to neuroinflammation some patents protecting the 
development of anti-inflammatory compounds have been registered for use in ALS 
[232], but to our knowledge, none are being developed as part of current ALS 
therapeutic strategies [231]. In this context, in the search for valid ALS therapies, the 
standard view of neuroinflammation, which has focused mainly on the cytotoxic 
activity of microglia, is not longer valid. Instead this view should be replaced by an 
integrative approach that involves a wide spectrum of microglial phenotypes and 
recognizes the dynamic interactions between microglia, neurons, immune cells, and 
astrocytes. 
 
9. CONCLUDING REMARKS 
The causes and pathophysiology of ALS are far from being clarified. Recent years have 
seen notable gene discoveries in ALS, but only very modest progress in treatment. In 
spite of the large body of evidence provided, many questions remain unanswered. For 
example: Why do some individuals carrying a pathogenic SOD1 or C9orf72 mutation 
never develop ALS or FTD? Are they resistant to the disease? What is the real role of 
the immune system in the pathogenesis of the disease? Answers to these questions 
should help us to understand ALS and to find therapeutic solutions for this devastating 
disease. 

































































The involvement of microglia in non-inflammatory functions challenges our concept of 
neuroinflammation and opens up new research posibilities in the neuron-microglia 
crosstalk. In this new scenario, mechanisms such as the fractalkine-CX3CR1 axis or 
MVs and exosome trafficking appear as central players in this relationship. As these 
new functions are progressively characterized, the pathophysiological mechanisms of 
ALS will hopefully be revelated. In this pursuit, molecular characterization of the 
different ALS clinical presentations must allow an integrated view of the disease and 
enable new effective strategies for diagnosing and treating the condition. In the 
meantime, we can only continue to work hard and hope that we will see soon a giant 
step forward for humankind in the treatment of this pernicious killer disease. 
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Figure 1: ALS viewed as a multifactorial disease with diverse clinical presentations and 
neurodegeneration patterns. a) Overlapping of ALS clinical manifestations and diverse 
pathologies depends on the main mutated genes, except for C9orf72, common to all 
diseases. b) Drawing represents ALS genetics as a continuum spectrum, ranging from a 
monogenic inherited disease (fALS) to idiopathic sALS, and with a decreasing gene 
penetrance. In this model, misfolded TDP-43 protein aggregation and 
neuroinflammation are the only pathological mechanisms common to all ALS 
phenotypes. 
 
Figure 2: Cellular processes involving altered responses of dysfunctional glia in ALS. 
Misfolded protein aggregates (MPA) induce motor neuron and astrocyte suffering and 
the neuronal release of glial activation signals. Reactive microglia mediate different 
pro-inflammatory and neuroprotective processes in coordination with astrocytes and 
requires increased energy consumption. Extracellular MPA also activates microglial 
phagocytic activity to remove aggregates, which results in microglial dysfunction that 
directly participates in neurodegeneration. Gene polymorphisms inducing decreased 
C9orf72 activity favor misfolded protein aggregation and microglial dysfunction (see 
text for details). 
  
Figure 3: Signaling systems involved in the ALS neuron-microglia-astrocyte crosstalk. 
Astrocytes and microglia modulate neuronal activity by sensing neurotransmitter 
release. Also, microglia have receptors to molecules released by astrocytes and vice-
versa. In ALS, reactive microglia and astrocytes mediate different neuroprotective 
(green arrows) and cytotoxic processes (red arrows) according to a diversity of signals 

































































from the injured motor neurons. This glial activation mobilizes the immune system, also 
proposed to trigger motor plaque injury and neurodegeneration. 5-HT, serotonin; Ach, 
acetylcholine; Ado, adenosine; BDNF, Brain-derived neurotrophic factor; bFGF, 
fibroblast growth factor-b; EAAT-1, excitatory amino acid transporter-1; GABA, γ-
aminobutyric acid; GDNF, glial cell-derived neurotrophic factor; Glu, glutamate; GSH, 
glutathione; IFNγ, interferon gamma; IGF-1, insulin-like growth factor-1; IL-1β, 4, 5, 6, 
10, interleukins 1beta, 4, 5, 6, 10; MVs, microvesicles; NMJ, neuromuscular junction; 
NO, nitric oxide; NT3, neurotrophin 3; ROS, reactive oxygen species; Tau, taurine; 
TGFβ, transforming growth factor beta, TNF-α, tumor necrosis factor alpha; VEGF, 
vascular endothelial growth factor; VIP, vasoactive intestinal peptide. 
 
































































Table 1: Major genes associated with ALS  
 
Gene Protein name Protein description and function.  ALS pathophysiology ALS association 
SOD1 
Cu/Zn Superoxide 
dismutase 1, soluble  
Soluble cytoplasmic protein, acting as a homodimer to 
convert endogenous but harmful superoxide radicals to 
molecular oxygen and hydrogen peroxide.  
Aggregate formation Cause  
FUS Fused in sarcoma 
Multifunctional protein component of the heterogeneous 
nuclear ribonucleoprotein (hnRNP) complex. The hnRNP 
complex is involved in pre-mRNA splicing and the export 
of fully processed mRNA to the cytoplasm.  




Chromosome 9 open 
reading frame 72 
This protein plays an important role in the regulation of 
endosomal trafficking, and has been shown to interact 
with Rab proteins that are involved in autophagy and 
endocytic transport.  
Blockade of nuclear-







DNA-binding protein 43 
Transcriptional repressor that binds to chromosomally 
integrated transactive response DNA and represses HIV-1 
transcription. It also regulates alternate splicing of the 
CFTR gene. 
TARDBP over-expression 
leads to deregulation of ER-
mitochondria interactions 
through VAPB and PTPIP51. 
Aggregate formation 
Cause 
UBQLN2 Ubiquilin 2 
Ubiquitin-like protein that physically associates with both 
proteasomes and ubiquitin ligases; and thus, are thought 
to functionally link the ubiquitination machinery to the 
proteasome to modify protein degradation. 
Protein aggregates activate, 




This protein contains a DNA/RNA helicase domain. This 







Spastic paraplegia 11 
(autosomal recessive). 
Spatacsin 
This protein is needed for the recycling of lysosomes from 
autophagic lysosome reformation. 
 







protein B and C 
Membrane protein found in plasmalemmal and 
intracellular vesicle membranes. It is found as a 
homodimer and as a heterodimer with VAPA. It can also 
interact with VAMP1 and VAMP2 and may be involved 
in vesicle trafficking. 
VAPB cytoplasmic 
aggregates triggers calcium 
dependent aberrant ER and 
Golgi structures and function 
Increased risk 
ATXN2 Ataxin 2 
Protein primarily localized to the Golgi apparatus with 
unknown function.  
Associate with TDP-43. ER 
stress leading to 
neurodegeneration 
Increased risk 
TBK1 TANK binding kinase 1 
Protein similar to IκB kinases that mediate NFκB 





unc-13 homolog A (C. 
elegans) 
Member of the UNC13 family. These proteins bind to 
phorbol esters and diacylglycerol and play important roles 







chemokine receptor 1 
Receptor for fractalkine, a transmembrane protein and 
chemokine involved in the adhesion and migration of 
leukocytes. In the CNS is expressed by microglia and 








Unknown. It interacts with human chromosome-
associated polypeptide (HCAP) and KIF3A/B, a kinesin 
superfamily protein in the nucleus. It is proposed to play a 
role in the interaction of chromosomes with ATPase 
motor proteins. 




EPHA4  EPH receptor A4 
Ephrin receptor subfamily of receptors with protein-
tyrosine kinase activity. It is implicated in developmental 





solute carrier family 11 
member 2 
Also known as DMT1, this protein transports divalent 
metals and is involved in iron absorption. Mutations in 
this gene are associated with hypochromic microcytic 
anemia with iron overload. 
Altered metal homeostasis. It 




Table shows examples of genes in which polymorphisms cause, increase the risk or modify progression rate of ALS. Not 
everyone carrying a disease-related mutation in these genes develops ALS, which suggests that other factors are needed to 
cause disease.  



































































Figure 1  
Figure 1: ALS viewed as a mult  
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Figure 2: Cellular processes involving altered responses of dysfunctional glia in ALS  
Figure 2  
172x133mm (300 x 300 DPI)  
 
 



































































Figure 3: Signaling systems involved in the ALS neuron-microglia-astrocyte crosstalk  
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